GSK plc (NYSE:GSK) Shares Purchased by Altrius Capital Management Inc

Altrius Capital Management Inc grew its stake in shares of GSK plc (NYSE:GSK - Free Report) by 8.9% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 216,000 shares of the pharmaceutical company's stock after acquiring an additional 17,578 shares during the period. GSK comprises approximately 2.0% of Altrius Capital Management Inc's holdings, making the stock its 13th biggest position. Altrius Capital Management Inc's holdings in GSK were worth $7,305,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds and other institutional investors also recently modified their holdings of GSK. FMR LLC increased its holdings in GSK by 8.3% in the third quarter. FMR LLC now owns 29,008,928 shares of the pharmaceutical company's stock valued at $1,185,885,000 after buying an additional 2,224,345 shares during the last quarter. Fisher Asset Management LLC grew its position in shares of GSK by 4.9% in the 3rd quarter. Fisher Asset Management LLC now owns 18,576,930 shares of the pharmaceutical company's stock worth $759,425,000 after acquiring an additional 870,449 shares in the last quarter. Hotchkis & Wiley Capital Management LLC increased its holdings in shares of GSK by 30.8% in the 3rd quarter. Hotchkis & Wiley Capital Management LLC now owns 3,542,143 shares of the pharmaceutical company's stock valued at $144,803,000 after acquiring an additional 833,080 shares during the last quarter. Miller Howard Investments Inc. NY acquired a new stake in shares of GSK during the 4th quarter valued at approximately $23,366,000. Finally, Bridgewater Associates LP lifted its stake in GSK by 107.3% during the third quarter. Bridgewater Associates LP now owns 965,836 shares of the pharmaceutical company's stock worth $39,483,000 after purchasing an additional 500,010 shares during the last quarter. Institutional investors own 15.74% of the company's stock.

GSK Stock Performance

GSK stock traded up $0.38 on Monday, reaching $37.97. The company's stock had a trading volume of 3,978,664 shares, compared to its average volume of 4,929,240. GSK plc has a 52 week low of $31.72 and a 52 week high of $45.92. The company has a debt-to-equity ratio of 1.12, a current ratio of 0.78 and a quick ratio of 0.52. The company has a market capitalization of $78.70 billion, a P/E ratio of 23.88, a price-to-earnings-growth ratio of 1.12 and a beta of 0.64. The firm has a fifty day moving average of $35.07 and a two-hundred day moving average of $37.20.

GSK (NYSE:GSK - Get Free Report) last released its quarterly earnings results on Wednesday, February 5th. The pharmaceutical company reported $0.59 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.44 by $0.15. GSK had a return on equity of 48.59% and a net margin of 8.13%. As a group, analysts predict that GSK plc will post 4.14 EPS for the current fiscal year.

GSK Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Thursday, April 10th. Stockholders of record on Friday, February 21st will be paid a $0.3932 dividend. This is a positive change from GSK's previous quarterly dividend of $0.39. This represents a $1.57 dividend on an annualized basis and a dividend yield of 4.14%. The ex-dividend date is Friday, February 21st. GSK's dividend payout ratio is currently 98.74%.

Wall Street Analyst Weigh In

GSK has been the subject of several recent research reports. Morgan Stanley began coverage on shares of GSK in a research note on Wednesday, February 12th. They set an "equal weight" rating for the company. Jefferies Financial Group downgraded shares of GSK from a "buy" rating to a "hold" rating and lowered their price objective for the company from $53.00 to $39.50 in a research report on Tuesday, November 12th. Deutsche Bank Aktiengesellschaft lowered shares of GSK from a "buy" rating to a "hold" rating in a research note on Friday, November 15th. Finally, StockNews.com upgraded GSK from a "buy" rating to a "strong-buy" rating in a research note on Friday, February 7th. Seven investment analysts have rated the stock with a hold rating and four have given a strong buy rating to the company. According to data from MarketBeat.com, GSK has an average rating of "Moderate Buy" and a consensus price target of $43.25.

GSK Company Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.